HC Wainwright Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI)
HC Wainwright reaffirmed their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $95.00 price target on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.63) EPS, […]
More Stories
Tullow Oil (LON:TLW) Stock Price Down 7.6% After Analyst Downgrade
Tullow Oil plc (LON:TLW – Get Free Report) fell 7.6% during mid-day trading on Monday after Shore Capital lowered their...
Tullow Oil (LON:TLW) Stock Price Down 7.6% on Analyst Downgrade
Tullow Oil plc (LON:TLW – Get Free Report)’s stock price dropped 7.6% during trading on Monday after Shore Capital lowered...
Tullow Oil (LON:TLW) Shares Down 7.6% on Analyst Downgrade
Shares of Tullow Oil plc (LON:TLW – Get Free Report) traded down 7.6% on Monday after Shore Capital lowered their...
Head-To-Head Contrast: Avient (NYSE:AVNT) & ASP Isotopes (NASDAQ:ASPI)
Avient (NYSE:AVNT – Get Free Report) and ASP Isotopes (NASDAQ:ASPI – Get Free Report) are both basic materials companies, but...
Innoviva (NASDAQ:INVA) versus Roche (OTCMKTS:RHHBY) Head to Head Review
Innoviva (NASDAQ:INVA – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is...
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $60.00 by Analysts at Chardan Capital
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective decreased by equities research analysts at Chardan Capital from...